SITE004-0243

withdrawn

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2022-12-07

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-05 (study day 15); relationship: not assessed

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-01-19 (study day 29); relationship: not assessed

severe assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-29 (study day 39); relationship: not assessed

moderate assessed

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-03-16 (study day 85); relationship: N

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-21 (study day 90); relationship: Y

Data queries

No data queries.